

## RESEARCH ARTICLE



# Sex-based disparities in dopamine agonist response in patients with restless legs syndrome

Maria P. Mogavero<sup>1,2</sup> | Elena Antelmi<sup>3,4</sup> | Giuseppe Lanza<sup>5,6</sup> |  
Sara Marelli<sup>1,2</sup> | Alessandra Castelnovo<sup>1,2</sup> | Michele Tinazzi<sup>3,7</sup> |  
Lourdes M. DelRosso<sup>8</sup> | Rosalia Silvestri<sup>9</sup> | Raffaele Ferri<sup>5</sup> |  
Luigi Ferini Strambi<sup>1,2</sup>

<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy

<sup>2</sup>Sleep Disorders Center, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy

<sup>3</sup>Neurology Unit, Parkinson Disease and Movement Disorders Division, AOUI, Verona, Italy

<sup>4</sup>DIMI Department of Engineering and Medicine of Innovation, University of Verona, Verona, Italy

<sup>5</sup>Clinical Neurophysiology Research Unit and Sleep Research Centre, Oasi Research Institute-IRCCS, Troina, Italy

<sup>6</sup>Department of Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy

<sup>7</sup>Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy

<sup>8</sup>University of California San Francisco, Fresno, California, USA

<sup>9</sup>Sleep Medicine Center, UOSD of Neurophysiopathology and Movement Disorders, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

## Correspondence

Raffaele Ferri, Oasi Research Institute-IRCCS, Via C. Ruggero 73, 94018 Troina, Italy.  
Email: [rferri@oasi.en.it](mailto:rferri@oasi.en.it)

## Funding information

Ministero della Salute, Grant/Award Number: RC-2787055

## Summary

This study aimed to investigate sex-related differences in the response to ropinirole and pramipexole in patients with restless legs syndrome (RLS). By analysing clinical parameters and polysomnographic (PSG) findings, we sought to elucidate the potential factors related to sex disparities modulating treatment responses and sleep quality in RLS. A total of 41 drug-free patients with RLS, aged  $\geq 18$  years, underwent two consecutive nocturnal PSG recordings, without medication at baseline; before the second night, 26 patients received an oral dose of 0.25 mg pramipexole whereas 15 received 0.5 mg ropinirole. After each PSG recording, patients self-evaluated the severity of their previous night symptoms by means of an ad hoc visual analogue scale (VAS). At baseline, sleep efficiency and percentage of Stage N2 tended to be higher in females while wakefulness after sleep onset was significantly higher in males. After treatment, total leg movements during sleep (LMS), periodic LMS (PLMS), and periodicity indexes were significantly lower in females than in males. The VAS score was lower after treatment in all patients, without differences between the two sexes. This study demonstrates a higher acute responsiveness of PLMS to dopamine agonists (pramipexole and ropinirole) in females than in males with RLS. These findings might be explained by differential sex-related expression of dopamine receptors, especially D<sub>3</sub>, within the central nervous system. In addition, our findings provide translational hints toward a better tailored and sex-specific approach to the treatment of RLS associated with PLMS, with dopamine agonist possibly associated with a better outcome in females than in males.

## KEYWORDS

dopamine agonists, isolated leg movements during sleep, periodic leg movements during sleep, restless legs syndrome, sex

Raffaele Ferri co-last author.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Author(s). *Journal of Sleep Research* published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.

## 1 | INTRODUCTION

Restless legs syndrome (RLS) is a highly heterogeneous sensorimotor disorder, both in terms of clinical manifestations, onset, and evolution of symptoms (with sex- and age-related differences), and in terms of response to pharmacological treatment (DelRosso, Mogavero, & Ferri, 2021; Manconi et al., 2021). Epidemiological studies reveal a higher prevalence of RLS in females compared to males from adolescence onwards (DelRosso, Mogavero, Baroni, et al., 2021; Manconi et al., 2021). In males, periodic leg movements during sleep (PLMS) seem to prevail, present in 80% of patients with RLS (Manconi et al., 2021), with a peak particularly in old age (Ferri et al., 2020), although in females an increase in periodicity has been highlighted in conjunction with menopause, probably correlated with hormonal variations (Mogavero, DelRosso, et al., 2024).

The aetiopathogenesis of RLS remains elusive, with various biological mechanisms and neurotransmitter pathways implicated in its pathophysiology, including altered sleep homeostasis and disrupted neural plasticity, affecting not only the hypothalamus–spinal dopaminergic circuit (nucleus A11) but also the basal ganglia and other structures of the limbic system (Lanza et al., 2022; Manconi et al., 2021; Mogavero et al., 2021). These pathways not only modulate the clinical presentation and severity of RLS but also influence its response to pharmacological interventions.

Polysomnography (PSG) studies have provided valuable insights into the neurophysiological characteristics of sleep in patients with RLS. PSG demonstrates marked alterations in sleep architecture in patients with RLS, including a significant reduction in sleep efficiency, total sleep time, and Stage N2 and rapid eye movement (REM) sleep, as well as an increase in sleep latency, wakefulness after sleep onset (WASO), Stage N1, and number of awakenings (Geng et al., 2022). Such findings underscore the complex interplay between RLS pathology and sleep disturbances, necessitating tailored therapeutic approaches.

Therapeutic strategies for RLS aim to alleviate symptoms and improve sleep quality. Although they are not considered to be first-line treatment anymore, due to the frequent occurrence of augmentation (Silber et al., 2021), dopamine agonists, such as ropinirole and pramipexole, represent mainstays of RLS treatment. These agents target dopaminergic pathways implicated in RLS pathophysiology, effectively reducing PLMS and associated autonomic phenomena (Inoue et al., 2010; Manconi, Ferri, Zucconi, Clemens, et al., 2011; Manconi, Ferri, Zucconi, Oldani, et al., 2011). Additionally,  $\alpha_2\delta$  ligands of calcium channels, now considered to be first-line treatments (Silber et al., 2021), have shown promise in ameliorating hyperarousability and hyperexcitability, as well as in enhancing deep sleep in patients with RLS (Garcia-Borreguero et al., 2002; Lanza et al., 2023; Winkelman & Jaros, 2018).

Despite the efficacy of these pharmacological interventions, sex-related differences in treatment response remain poorly understood. While RLS exhibits pronounced sex disparities in prevalence and clinical presentation, data regarding the impact of sex on therapeutic outcomes are limited (Manconi et al., 2021). Understanding sex-based

variations in treatment response is essential for optimising RLS management and enhancing patient outcomes.

The present study aimed to investigate sex-related factors influencing the acute response to dopamine agonists, specifically ropinirole and pramipexole, in adult patients with RLS. By analysing both clinical parameters and PSG findings, especially PLMS known to be very little affected by the placebo effect (Fulda & Wetter, 2008), we sought to elucidate the potential implications of sex disparities on treatment efficacy and sleep quality in RLS management.

## 2 | METHODS

### 2.1 | Patients

We retrospectively recruited 41 consecutive, drug-free patients diagnosed with RLS (26 females and 15 males) with a mean (standard deviation [SD]) age of 59.7 (11.7) years, who provided their informed consent according to the Declaration of Helsinki.

The diagnosis of RLS was carried out according to the following five International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria (Allen et al., 2014), through a semi-structured interview. Patients with a sleep disorder diagnosis other than RLS, any psychiatric diagnosis or use of antidepressants (Ferri et al., 2022; Ferri et al., 2023), neurodevelopmental delay, use of central nervous system drugs within the year prior to the study or use of any drug or medication for RLS for 3 weeks before the PSG recording were excluded. Also, patients with an apnea-hypopnea index >10 events/h of sleep were excluded. None of the patients had any additional significant medical or neurological disorder; therefore, none was taking other medications. The score at the IRLSSG rating scale (IRLS) (Walters et al., 2003) was also obtained.

Patients underwent two consecutive nocturnal PSG recordings. No medication was administered before the first night recording (baseline); before the second night recording, 26 patients (18 females and eight males) received a single oral dose of 0.25 mg pramipexole and 15 patients (eight females and seven males) received a single oral dose of 0.5 mg ropinirole at ~9.00 p.m. We selected these dosages as they typically serve as the initial doses when tapering therapy. There is a lack of data regarding the equivalent dosage between these two compounds in treating RLS. However, based on Parkinson's disease literature, the approximate equivalence ratio between pramipexole and ropinirole ranges from 1:2 to 1:4 (Linazasoro, 2008). Furthermore, these dosages are in line with the dosages suggested by the current treatment guidelines for RLS (Silber et al., 2021). No plasma levels were assessed because it has previously been reported that pharmacokinetics and pharmacodynamics of both pramipexole and ropinirole are not different between sexes (Contin et al., 2019; Kaye & Nicholls, 2000; Kompoliti et al., 2002). Bedtime was based on the usual individual bedtime and ranged between 9:30 and 11:00 p.m.

In the morning, after each PSG recording, all patients evaluated the severity of their previous night symptoms by means of a visual analogue scale (VAS) and reported eventual side-effects.

Patients provided informed consent to the study, which was approved by the Oasi Research Institute Ethics Committee.

## 2.2 | Polysomnographic recording and scoring

All the patients underwent a full-night PSG recording, which included electroencephalogram (at least three channels, one frontal, one central and one occipital, referred to the contralateral earlobe); electro-oculogram (two channels), electromyogram (EMG) of the submental muscle and of both tibialis anterior muscles, and electrocardiogram (one derivation). The EMG signals from the chin and both tibialis anterior muscles were band-pass filtered at 10–100 Hz, with a notch filter at 50 Hz. At the beginning of each recording session, the amplitude of the EMG signal from the two tibialis anterior muscles was assured to be  $<2 \mu\text{V}$  at rest.

Sleep stages were visually scored on 30-s epochs and all leg movements during sleep (LMS) were identified following standard criteria (Ferri et al., 2016), followed by the computation of a series of parameters including, in particular: (a) total LMS index,  $n/h$ ; (b) PLMS index,  $n/h$ : LMS included in regular and non-interrupted sequences of at least four movements with onset-to-onset inter-movement interval (IMI) 10–90 s; (c) short-interval LMS (SILMS) index,  $n/h$ : LMS with preceding IMI  $<10$  s; (d) isolated LMS (ISOLMS) index,  $n/h$ : LMS with IMI  $>90$  s and LMS with IMI 10–90 s not meeting all the criteria for PLMS; (e) periodicity index: PLMS index/total LMS index ratio. Respiratory-related leg movements were not excluded from the counts because patients with an apnea-hypopnea index  $>10$  events/h of sleep were excluded and not enrolled. In addition, there is no general agreement on the definition of the rules for the identification of these movements (Ferri et al., 2016) and respiratory-related LMS can be true PLMS (Manconi et al., 2014).

## 2.3 | Statistical analysis

Differences between the two groups were assessed by means of the Student's  $t$ -test, followed by the Bonferroni correction for multiple comparisons and supported by the Cohen's  $d$  effect size

(Cohen, 1988). For the analysis of frequencies, the chi-square test was used. Correlations were assessed by multiple regression analysis. The commercially available Statistica software package (StatSoft, Inc., 2001. STATISTICA data analysis software system, version 6; [www.statsoft.com](http://www.statsoft.com)) was used. Differences were considered significant for  $p < 0.05$ .

## 3 | RESULTS

Females were slightly younger than men, but the difference was not statistically significant (mean [SD] 58.0 [10.51] versus 62.6 [13.29] years,  $t$ -value  $-1.250$ , non-significant [NS]). Similarly, the IRLS score obtained from females and males was not significantly different (mean [SD] 25.1 [5.10] versus 24.1 [5.69],  $t$ -value 0.579, NS). We also checked for eventual differences at baseline between patients taking pramipexole and those taking ropinirole (Table 1) and found no significant differences in age, IRLS score, VAS score, and PLMS index. None of the patients reported side-effects after the treatment night.

### 3.1 | Sleep architecture

Table 2 shows the comparison of sleep architecture parameters obtained at baseline and during the treatment night in females and males. At baseline, we found only a small difference in the number of awakenings, which tended to be higher in males with a medium-to-large effect size; however, the difference was not significant after Bonferroni correction. For the treatment night, differences were found involving sleep efficiency and percentage of sleep Stage N2 (higher in females), which did not pass the Bonferroni correction but were characterised by a medium-to-large effect size. Conversely, WASO was significantly higher in males, with a significant  $p$  value after Bonferroni correction and a large effect size. The bottom part of the table reports the statistical comparison of the change in each parameter, expressed as a percentage of the baseline value. With this analysis we found a significant (not after Bonferroni correction but with a large effect size) difference of change in sleep Stage N2, smaller in males.

**TABLE 1** Demographic and clinical features of patients.

| Variable                         | Pramipexole ( $n = 26$ ) | Ropinirole ( $n = 15$ ) | Statistics               |
|----------------------------------|--------------------------|-------------------------|--------------------------|
| Sex, female/male, $n$            | 18/8                     | 8/7                     | chi-square 1.04, NS      |
| Age, years, mean (SD)            | 59.6 (10.04)             | 59.8 (14.45)            | $t$ -value $-0.046$ , NS |
| IRLS score, mean (SD)            | 25.9 (5.64)              | 22.7 (4.05)             | $t$ -value 1.963, NS     |
| PLMS index, $n/h$ , mean (SD)    | 50.6 (49.67)             | 53.6 (46.17)            | $t$ -value $-0.186$ , NS |
| VAS score at baseline, mean (SD) | 7.4 (1.63)               | 7.1 (1.21)              | $t$ -value 0.690, NS     |
| Comorbidities                    | None                     | None                    | –                        |
| Treatment                        | None                     | None                    | –                        |

Abbreviations: IRLS, International Restless Legs Syndrome Study Group rating scale; NS, non-significant; PLMS, periodic leg movements during sleep; SD, standard deviation; VAS, visual analogue scale.

**TABLE 2** Comparison of sleep architecture parameters obtained at baseline and during the treatment night in females and males; the comparison of the change of each parameter, expressed as a percentage of the baseline value is also reported.

|                        | Females (n = 26) | Males (n = 15) | Student's t-test |         | Effect size<br>Cohen's d |
|------------------------|------------------|----------------|------------------|---------|--------------------------|
| Variable               | Mean (SD)        | Mean (SD)      | t-value          | p       |                          |
| Baseline               |                  |                |                  |         |                          |
| Time in bed, min       | 518.0 (90.04)    | 492.8 (71.75)  | 0.925            | NS      | 0.310                    |
| Sleep period time, min | 482.5 (90.55)    | 454.1 (82.81)  | 0.995            | NS      | 0.327                    |
| Total sleep time, min  | 358.4 (113.84)   | 332.2 (101.14) | 0.739            | NS      | 0.243                    |
| Sleep latency, min     | 26.1 (23.97)     | 24.3 (37.21)   | 0.190            | NS      | 0.058                    |
| Stage R latency, min   | 137.4 (92.98)    | 103.9 (69.29)  | 1.210            | NS      | 0.409                    |
| Stage shifts, n/h      | 10.9 (3.91)      | 13.4 (4.49)    | −1.852           | NS      | −0.594                   |
| Awakenings, n/h        | 4.7 (2.62)       | 6.4 (1.90)     | −2.103           | 0.042   | −0.743                   |
| Sleep efficiency, %    | 68.4 (18.78)     | 67.0 (15.07)   | 0.253            | NS      | 0.082                    |
| Stage W, %             | 26.8 (18.92)     | 27.5 (13.86)   | −0.131           | NS      | −0.042                   |
| Stage N1, %            | 5.2 (5.45)       | 6.2 (4.92)     | −0.613           | NS      | −0.193                   |
| Stage N2, %            | 39.6 (11.22)     | 41.1 (11.34)   | −0.417           | NS      | −0.133                   |
| Stage N3, %            | 15.3 (8.53)      | 12.1 (8.23)    | 1.191            | NS      | 0.382                    |
| Stage R, %             | 13.2 (7.84)      | 13.1 (7.30)    | 0.011            | NS      | 0.013                    |
| Treatment              |                  |                |                  |         |                          |
| Time in bed, min       | 515.2 (44.59)    | 515.3 (56.71)  | −0.007           | NS      | −0.002                   |
| Sleep period time, min | 481.8 (52.29)    | 486.5 (54.71)  | −0.272           | NS      | −0.088                   |
| Total sleep time, min  | 413.6 (56.50)    | 370.9 (80.98)  | 1.983            | NS      | 0.612                    |
| Sleep latency, min     | 20.6 (19.20)     | 17.7 (26.13)   | 0.412            | NS      | 0.126                    |
| Stage R latency, min   | 137.9 (94.72)    | 110.1 (53.23)  | 1.042            | NS      | 0.362                    |
| Stage shifts, n/h      | 13.2 (4.24)      | 15.4 (5.90)    | −1.365           | NS      | −0.428                   |
| Awakenings, n/h        | 5.6 (2.62)       | 7.4 (3.82)     | −1.873           | NS      | −0.550                   |
| Sleep efficiency, %    | 80.3 (8.13)      | 72.2 (14.21)   | 2.325            | 0.025   | 0.700                    |
| Stage W, %             | 14.1 (7.03)      | 24.2 (11.81)   | −3.432           | 0.0014* | −1.039                   |
| Stage N1, %            | 4.5 (3.69)       | 5.6 (4.64)     | −0.862           | NS      | −0.262                   |
| Stage N2, %            | 52.9 (9.95)      | 43.8 (12.66)   | 2.538            | 0.015   | 0.799                    |
| Stage N3, %            | 15.1 (7.13)      | 14.5 (9.37)    | 0.221            | NS      | 0.072                    |
| Stage R, %             | 13.5 (7.15)      | 11.9 (4.22)    | 0.781            | NS      | 0.273                    |
| Change                 |                  |                |                  |         |                          |
| Time in bed, %         | 5.9 (44.56)      | 6.4 (17.45)    | −0.042           | NS      | −0.015                   |
| Sleep period time, %   | 6.7 (45.85)      | 10.0 (20.77)   | −0.257           | NS      | −0.093                   |
| Total sleep time, %    | 42.6 (106.49)    | 16.6 (26.07)   | 0.926            | NS      | 0.335                    |
| Sleep latency, %       | 224.9 (818.81)   | 233.6 (389.08) | −0.039           | NS      | −0.014                   |
| Stage R latency, %     | −126.4 (746.01)  | −43.2 (252.10) | −0.417           | NS      | −0.149                   |
| Stage shifts, %        | 30.1 (46.39)     | 19.1 (35.71)   | 0.791            | NS      | 0.266                    |
| Awakenings, %          | 55.5 (103.09)    | 21.7 (62.65)   | 1.150            | NS      | 0.396                    |
| Sleep efficiency, %    | 30.3 (55.61)     | 10.7 (21.61)   | 1.310            | NS      | 0.465                    |
| Stage W, %             | 4.1 (154.13)     | −0.1 (54.26)   | 0.103            | NS      | 0.036                    |
| Stage N1, %            | 31.8 (103.09)    | 29.8 (93.82)   | 0.062            | NS      | 0.020                    |
| Stage N2, %            | 40.6 (35.95)     | 11.8 (34.99)   | 2.495            | 0.017   | 0.812                    |
| Stage N3, %            | −13.1 (42.93)    | 111.6 (333.94) | −1.781           | NS      | −0.524                   |
| Stage R, %             | 34.4 (138.33)    | −2.8 (48.04)   | 0.968            | NS      | 0.359                    |

\*Significant after Bonferroni correction.

Abbreviations: NS, non-significant; SD, standard deviation.

### 3.2 | Leg movement activity during sleep

Similarly to the previous table, Table 3 shows the same analysis performed for leg movement activity parameters obtained at baseline and during the treatment night in females and males. There was no significant difference at baseline for these parameters and effect sizes were small or medium. On the contrary, during the treatment night, total LMS, PLMS, and periodicity indexes were significantly (also after Bonferroni correction) lower in females than in males, accompanied by large effect sizes. Also the SILMS index tended to be lower in females, but the *p* value was not significant after Bonferroni correction, although the effect size almost reached the value of 0.8, considered large by Cohen (Cohen, 1988). The analysis of the changes, expressed as percentages of the baseline parameters, confirmed the significant differences found for the treatment night.

**TABLE 3** Comparison of leg movement activity parameters obtained at baseline and during the treatment night in females and males; the comparison of the change of each parameter, expressed as a percentage of the baseline value is also reported.

| Variable             | Females (n = 26)<br>Mean (SD) | Males (n = 15)<br>Mean (SD) | Student's t-test |         | Effect size<br>Cohen's d |
|----------------------|-------------------------------|-----------------------------|------------------|---------|--------------------------|
|                      |                               |                             | t-value          | p       |                          |
| Baseline             |                               |                             |                  |         |                          |
| Total LMS index, n/h | 60.4 (54.85)                  | 84.3 (65.23)                | −1.253           | NS      | −0.396                   |
| PLMS index, n/h      | 43.2 (41.76)                  | 66.4 (55.36)                | −1.520           | NS      | −0.473                   |
| SILMS index, n/h     | 6.6 (10.71)                   | 7.3 (9.42)                  | −0.201           | NS      | −0.066                   |
| ISOLMS index, n/h    | 10.5 (6.63)                   | 10.5 (6.14)                 | −0.008           | NS      | −0.003                   |
| Periodicity Index    | 0.691 (0.141)                 | 0.732 (0.183)               | −0.791           | NS      | −0.247                   |
| PLMS duration, s     | 3.1 (0.93)                    | 2.9 (0.85)                  | 0.856            | NS      | 0.281                    |
| SILMS duration, s    | 2.8 (0.75)                    | 2.8 (0.93)                  | −0.102           | NS      | −0.032                   |
| ISOLMS duration, s   | 3.5 (1.01)                    | 3.0 (0.91)                  | 1.444            | NS      | 0.476                    |
| Treatment            |                               |                             |                  |         |                          |
| Total LMS index, n/h | 15.7 (10.24)                  | 32.1 (23.03)                | −3.149           | 0.0031* | −0.920                   |
| PLMS index, n/h      | 3.9 (5.59)                    | 17.3 (21.61)                | −3.014           | 0.0045* | −0.848                   |
| SILMS index, n/h     | 1.9 (2.25)                    | 3.6 (2.37)                  | −2.282           | 0.028   | −0.734                   |
| ISOLMS index, n/h    | 9.9 (4.17)                    | 11.2 (5.61)                 | −0.849           | NS      | −0.264                   |
| Periodicity index    | 0.178 (0.176)                 | 0.396 (0.266)               | −3.159           | 0.003*  | −0.966                   |
| PLMS duration, s     | 3.5 (1.55)                    | 2.9 (0.95)                  | 1.511            | NS      | 0.536                    |
| SILMS duration, s    | 2.9 (1.21)                    | 2.8 (1.02)                  | 0.211            | NS      | 0.071                    |
| ISOLMS duration, s   | 3.7 (0.90)                    | 3.2 (0.90)                  | 1.728            | NS      | 0.560                    |
| Change               |                               |                             |                  |         |                          |
| Total LMS index, %   | −63.9 (21.26)                 | −45.3 (40.77)               | −1.924           | NS      | −0.571                   |
| PLMS index, %        | −89.2 (14.68)                 | −66.0 (30.31)               | −3.300           | 0.002*  | −0.972                   |
| SILMS index, %       | −49.6 (35.15)                 | 53.1 (257.78)               | −2.016           | 0.05    | −0.558                   |
| ISOLMS index, %      | 11.3 (45.24)                  | 24.0 (55.07)                | −0.798           | NS      | −0.251                   |
| Periodicity Index    | −73.6 (26.54)                 | −45.4 (32.24)               | −3.027           | 0.0044* | −0.954                   |
| PLMS duration, %     | −13.4 (81.70)                 | 4.8 (36.44)                 | −0.812           | NS      | −0.287                   |
| SILMS duration, %    | 4.8 (54.75)                   | 18.3 (99.25)                | −0.564           | NS      | −0.168                   |
| ISOLMS duration, %   | 12.5 (33.61)                  | 13.3 (41.52)                | −0.068           | NS      | −0.021                   |


\*Significant after Bonferroni correction.

Abbreviations: ISOLMS, isolated leg movements during sleep; LMS, leg movements during sleep; NS, non-significant; PLMS, periodic leg movements during sleep; SD, standard deviation; SILMS, short-interval leg movements during sleep.

Finally, Figure 1 shows in a graphical way the distribution of inter-movement intervals obtained at baseline and during the treatment night in females and males.

### 3.3 | Visual analogue scale

The VAS score was very evidently lower after treatment in all patients; also, the score obtained in females and in males was not significantly different after both the baseline recording (mean [SD] 7.3 [1.49] versus 7.2 [1.40], *t*-value 0.306, NS) and the treatment night (mean [SD] 1.3 [1.45] versus 1.3 [1.49], *t*-value 0.000, NS); consequently, also the difference between the two nights was not different between females and males (mean [SD] −6.0 [1.97] versus −5.8 [1.64], *t*-value −0.242, NS).



**FIGURE 1** Distribution of inter-movement intervals obtained at baseline and during the treatment night in females and males.

## 4 | DISCUSSION

### 4.1 | Main findings

Pramipexole and ropinirole have long been recognised for their beneficial effects in the management of RLS. These dopamine agonists have demonstrated efficacy in alleviating symptoms such as uncomfortable sensations in the legs, restlessness, and disrupted sleep, thereby improving the quality of life for individuals with RLS (Ferri et al., 2010; Manconi et al., 2007; Manconi et al., 2021; Manconi, Ferri, Zucconi, Oldani, et al., 2011). Regarding PSG parameters, studies unanimously demonstrate efficacy in reducing PLMS, even at low dosage and both in acute and chronic settings, with no substantial differences between ropinirole and pramipexole (Manconi, Ferri, Zucconi, Clemens, et al., 2011; Manconi, Ferri, Zucconi, Oldani, et al., 2011); while there appear to be no alterations in sleep architecture, even in chronic usage and at maximum dosages permitted according to guidelines, except for a slight increase in Stage N2 highlighted in a few studies (Allen et al., 2004; Bliwise et al., 2005; Ferri et al., 2010; Saletu et al., 2002).

However, despite their effectiveness, they are now often considered second-line treatments in chronic persistent RLS due to the frequent development of augmentation, a phenomenon where symptoms worsen over time with continued use (Garcia-Borreguero et al., 2018; Silber et al., 2021). However, in refractory RLS the guidelines recommend, among the options, combined therapy (dopamine agonist plus  $\alpha_2\delta$  ligand) (Silber et al., 2021). Augmentation can lead to increased severity and frequency of symptoms, diminishing the overall therapeutic benefit of these medications. As a result, healthcare providers are increasingly cautious in prescribing pramipexole and ropinirole as first-line options, opting for alternative treatments or combined therapies to mitigate the risk of augmentation and ensure optimal management of RLS symptoms. Sex differences in augmentation do not seem to have been reported (Liu et al., 2016); however, in light of the results of this study and the effects of dopamine agonists on sleep structure, previously described, the use of dopamine agonists in RLS may be a more suitable treatment option for females than for males, although a significantly better subjective clinical effect in females has yet to be demonstrated. Of foremost importance remains weighing the benefits and potential risks of augmentation and the fact that long-term use of dopamine agonists reduces the response to  $\alpha_2\delta$  ligands of calcium channels (Garcia-Borreguero et al., 2019).

On the other hand, dopamine agonists are effective in modulating the increases in heart rate and blood pressure associated with PLMS (Manconi, Ferri, Zucconi, Clemens, et al., 2011; Rocchi et al., 2015), an important factor in cardiovascular risk prevention. There are no guidelines to treat PLMS in the absence of RLS symptoms; however, a recent meta-analysis has highlighted a greater risk of stroke associated with PLMS, regardless of the presence of RLS symptoms (Bassetti et al., 2020). One of the main findings of our study is a greater reduction in PLMS in females compared to males, due to the administration of dopamine agonists (Figure 1). Considering that pharmacokinetics and pharmacodynamics of both pramipexole and ropinirole are not different between sexes, as reported in the literature (Contin et al., 2019; Kaye & Nicholls, 2000; Kompolti et al., 2002), there are other factors probably underlying these findings.

The fact that these drugs act mainly in females and that, as found in our previous study, there seems to be a greater impact of PLMS especially with menopause (Mogavero, DelRosso, et al., 2024), a period from which females are at greater cardiovascular risk (Mehta & Manson, 2024), their use could represent a valuable aid in preventing cardiac issues in females affected by RLS and PLMS. In addition, sex differences observed in the prevalence of PLMS have led to the hypothesis of a possible role of hormonal factors implicated in their (still unknown) pathogenesis (Mogavero, DelRosso, et al., 2024), and recent studies on the transcriptome in patients with RLS have confirmed with biological evidence an overexpression of the oestrogen signalling pathway (Mogavero, Salemi, et al., 2024). In this context, it is important to emphasise that oestradiol acutely and rapidly regulates dopamine release in females and dopamine re-uptake in males (Yuest et al., 2019), so the differences observed in the response to dopamine agonists between males and females in our study could be attributed

to hormonal differences between the two sexes, resulting in a different modulation of the dopaminergic system.

Dopamine agonists are known for their preferential action on dopamine D<sub>3</sub> receptors, which are implicated in the pathophysiology of RLS (Clemens & Ghorayeb, 2019). Although they are now considered as second-line treatments, by administering pramipexole and ropinirole acutely, researchers can elucidate the immediate effects of D<sub>3</sub> receptor activation on RLS symptoms and related biological processes. In addition, the immediate effects of low doses of pramipexole and ropinirole render them suitable for on-demand treatment and as a supportive tool for differential diagnosis in complex cases (Manconi, Ferri, Zucconi, Oldani, et al., 2011).

Emerging research suggests that there may be differences in the expression of dopamine D<sub>3</sub> receptors between females and males. While our understanding of these sex-specific variations is still evolving, preliminary studies indicate potential disparities in the density and distribution of D<sub>3</sub> receptors in the brain (Brown et al., 2012; Williams et al., 2021). These differences may contribute to variations in dopamine signalling and neurotransmission, potentially influencing various physiological and behavioural processes. For instance, alterations in D<sub>3</sub> receptor expression have been implicated in conditions such as substance abuse disorders, attention deficit hyperactivity disorder, depression and anxiety, schizophrenia, and Parkinson's disease, which often manifest differently between sexes (Bao & Swaab, 2010; Sokoloff & Le Foll, 2017) and are often associated with RLS (Manconi et al., 2021). Therefore, the administration of dopamine agonists in RLS comorbid with these pathologies could be particularly useful, especially in females. Further investigation into the complexity of D<sub>3</sub> receptor expression in females and males holds promise for elucidating the underlying mechanisms of sex differences in brain function and behaviour, with implications for personalised medicine approaches tailored to each sex.

The expression of dopamine D<sub>3</sub> receptors appears to vary between individuals, and whether they are more expressed in females compared to males is still an area of ongoing research and debate. While some studies suggest potential differences in D<sub>3</sub> receptor expression between sexes (Brown et al., 2012; Williams et al., 2021), the findings are not consistent across all research. Factors such as age, hormonal fluctuations, and genetic predispositions, as well as epigenetic factors, may also influence D<sub>3</sub> receptor expression. Therefore, it is essential to interpret the available evidence cautiously and await further research to draw definitive conclusions regarding the expression of D<sub>3</sub> receptors in females versus males.

Regarding alterations in sleep architecture, we did not find substantial variations induced by dopamine agonists, in agreement with previously described findings, although there appears to be an increase in Stage N2 in females compared to males and WASO significantly higher in males compared to females. These findings may be due to the greater reduction in PLMS in females compared to males, considering that these movements are mainly distributed in this N2 sleep stage (Ferri, 2012).

Finally, the VAS score did not show clinical differences between females and males, although objective PLMS data demonstrated

significant differences between the sexes; this aspect supports the importance of using PSG in the management of RLS, although both international diagnostic criteria and treatment guidelines do not include it. It is undeniable that knowledge of the effects of therapies used in RLS on PSG parameters is important in order to restore and preserve the physiological architecture of sleep and its homeostasis. In addition, the evaluation of these parameters based on sex differences allows further stratification of patient types, with a targeted approach that may improve therapeutic response and reduce the risk of disease chronicity and onset of side-effects.

This seems to be the first study to have evaluated sex differences regarding a different PLMS response to pharmacological treatment in RLS, despite the marked differences between males and females found in this disorder (Kim et al., 2024; Manconi et al., 2021); this aspect has important clinical implications, in fact also recent research in other branches of medicine emphasises sex-related differences in the pharmacokinetics and pharmacodynamics of therapies used in arterial hypertension or myocardial ischaemia (Medzikovic et al., 2023; Tamargo et al., 2023), highlighting an important emerging topic in the field of Personalised and Precision Medicine and the need to consider this aspect in pharmacological guidelines. Therefore, it would be appropriate to evaluate a different sex-related approach also in RLS.

## 4.2 | Limitations

The primary limitation of this study is that we relied on a convenience sample of patients, lacking the opportunity to conduct a sample size analysis beforehand. Additionally, the absence of information on potential sex differences in response to dopamine agonist treatment in RLS further compounds this limitation. Nevertheless, it can be inferred that with our sample size consisting of 26 females and 15 males, we achieve a statistical power of 80% at an alpha level of 0.05 for comparisons featuring an effect size of 0.82 (large). Notably, our results also demonstrate effect sizes surpassing this threshold, thus affirming the robustness of our analysis.

Utilising two distinct dopamine agonists, namely pramipexole and ropinirole, could be perceived as an added constraint in this study. Nonetheless, we have previously documented a significant equivalence in the effects of these two compounds on sleep architecture, PLMS, and clinical outcomes among patients with RLS (Manconi, Ferri, Zucconi, Oldani, et al., 2011). Furthermore, it has been observed that the similarities in terms of efficacy and side-effects between pramipexole and ropinirole likely stem from their somewhat comparable pharmacokinetic and pharmacodynamic profiles (Manconi, Ferri, Zucconi, Oldani, et al., 2011). Both drugs act as preferential D<sub>3</sub> agonists, as evidenced by their inhibition constants (K<sub>i</sub>) in nmol/L: pramipexole at 0.5 and ropinirole at 2.9 nmol/L. They share similarities in elimination half-life (pramipexole: 8–12 h; ropinirole: 6 h), oral bioavailability (pramipexole: >90%; ropinirole: 50%), protein binding (pramipexole: 15%; ropinirole: 20–40%), and clearance (pramipexole: 30 L/h; ropinirole: 47 L/h) (Kvernmo et al., 2008). This prior evidence validates the

amalgamation of these patient cohorts in the present study, also supported by an additional analysis we ran on leg movement parameters, separately for patients taking pramipexole or ropinirole, that showed substantially similar sex differences (supplementary Table S1).

Lastly, our findings pertain to the acute effects of pramipexole and ropinirole and should not be directly extrapolated to their long-term effects. Nonetheless, they offer valuable insights into the biological mechanisms underlying sex differences in RLS, which can inform treatment recommendations in future studies.

## 5 | CONCLUSIONS

In conclusion, our study results reveal sex differences in response to dopamine agonists among patients with RLS. These findings align with recent research emphasising sex disparities in the pharmacokinetics and pharmacodynamics of cardiovascular therapies, underscoring an important emerging aspect within the field of Personalised and Precision Medicine that warrants consideration in future pharmacological guidelines. The present findings offer translational insights toward a more precisely tailored and sex-specific approach to RLS treatment.

### AUTHOR CONTRIBUTIONS

**Maria P. Mogavero:** Conceptualization; investigation; supervision; writing – original draft; writing – review and editing. **Elena Antelmi:** Writing – review and editing. **Giuseppe Lanza:** Writing – review and editing; writing – original draft. **Sara Marelli:** Writing – review and editing. **Alessandra Castelnovo:** Writing – review and editing. **Michele Tinazzi:** Writing – review and editing. **Lourdes M. DelRosso:** Writing – review and editing. **Rosalía Silvestri:** Writing – review and editing. **Raffaele Ferri:** Methodology; formal analysis; data curation; supervision; writing – original draft; writing – review and editing; funding acquisition; visualization. **Luigi Ferini Strambi:** Supervision; writing – review and editing.

### ACKNOWLEDGEMENTS

This study was partially supported by a grant from the Italian Ministry of Health ‘Ricerca Corrente’ (RC number: 2787055) (Dr Raffaele Ferri). Open access funding provided by BIBLIOSAN.

### CONFLICT OF INTEREST STATEMENT

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

### STUDY SUBJECTS OR COHORTS OVERLAP

Of note, a subset of the data presented in this study have been reported in previous studies (Manconi et al., 2007; Manconi, Ferri,

Zucconi, Oldani, et al., 2011) assessing PLMS response to dopamine agonists.

### ORCID

Maria P. Mogavero  <https://orcid.org/0000-0001-6662-2281>  
Elena Antelmi  <https://orcid.org/0000-0003-1739-6139>  
Giuseppe Lanza  <https://orcid.org/0000-0002-5659-662X>  
Sara Marelli  <https://orcid.org/0000-0003-0074-5371>  
Alessandra Castelnovo  <https://orcid.org/0000-0001-7037-0208>  
Michele Tinazzi  <https://orcid.org/0000-0002-2370-7063>  
Lourdes M. DelRosso  <https://orcid.org/0000-0003-3349-8426>  
Rosalía Silvestri  <https://orcid.org/0000-0002-1800-032X>  
Raffaele Ferri  <https://orcid.org/0000-0001-6937-3065>  
Luigi Ferini Strambi  <https://orcid.org/0000-0003-2867-5424>

### REFERENCES

- Allen, R., Becker, P. M., Bogan, R., Schmidt, M., Kushida, C. A., Fry, J. M., Poceta, J. S., & Winslow, D. (2004). Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. *Sleep*, 27(5), 907–914. <https://doi.org/10.1093/sleep/27.5.907>
- Allen, R. P., Picchietti, D. L., Garcia-Borreguero, D., Ondo, W. G., Walters, A. S., Winkelman, J. W., Zucconi, M., Ferri, R., Trenkwalder, C., Lee, H. B., & International Restless Legs Syndrome Study, Group. (2014). Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: Updated international restless legs syndrome study group (IRLSSG) consensus criteria – history, rationale, description, and significance. *Sleep Medicine*, 15(8), 860–873. <https://doi.org/10.1016/j.sleep.2014.03.025>
- Bao, A.-M., & Swaab, D. F. (2010). Sex differences in the brain, behavior, and neuropsychiatric disorders. *The Neuroscientist*, 16(5), 550–565.
- Bassetti, C. L. A., Randerath, W., Vignatelli, L., Ferini-Strambi, L., Brill, A. K., Bonsignore, M. R., Grote, L., Jennum, P., Leys, D., Minnerup, J., Nobili, L., Tonia, T., Morgan, R., Kerry, J., Riha, R., McNicholas, W. T., & Papavasileiou, V. (2020). EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke. *The European Respiratory Journal*, 55(4), 1901104. <https://doi.org/10.1183/13993003.01104-2019>
- Blivise, D. L., Freeman, A., Ingram, C. D., Rye, D. B., Chakravorty, S., & Watts, R. L. (2005). Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. *Sleep Medicine*, 6(2), 141–147. <https://doi.org/10.1016/j.sleep.2004.12.002>
- Brown, A. K., Mandelkern, M. A., Farahi, J., Robertson, C., Ghahremani, D. G., Sumerel, B., Moallem, N., & London, E. D. (2012). Sex differences in striatal dopamine D2/D3 receptor availability in smokers and non-smokers. *International Journal of Neuropsychopharmacology*, 15(7), 989–994.
- Clemens, S., & Ghorayeb, I. (2019). D3 and D1 receptors: The yin and Yang in the treatment of restless legs syndrome with dopaminergics. *Advances in Pharmacology*, 84, 79–100. <https://doi.org/10.1016/bs.apha.2019.01.002>
- Cohen, J. (1988). *Statistical power analysis for the behavioral sciences* (2nd ed.). Erlbaum.
- Contin, M., Lopane, G., Mohamed, S., Calandra-Buonaura, G., Capellari, S., De Massis, P., Nasseti, S., Perrone, A., Riva, R., Sambati, L., Scaglione, C., & Cortelli, P. (2019). Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease. *Parkinsonism & Related Disorders*, 61, 111–117. <https://doi.org/10.1016/j.parkreldis.2018.11.007>
- DelRosso, L. M., Mogavero, M. P., Baroni, A., Bruni, O., & Ferri, R. (2021). Restless legs syndrome in children and adolescents. *Child and*

- Adolescent Psychiatric Clinics of North America, 30(1), 143–157. <https://doi.org/10.1016/j.chc.2020.08.010>
- DelRosso, L. M., Mogavero, M. P., & Ferri, R. (2021). Restless sleep disorder, restless legs syndrome, and periodic limb movement disorder-sleep in motion! *Pediatric Pulmonology*, 57(81879–1886), 1879–1886. <https://doi.org/10.1002/ppul.25305>
- Ferri, R. (2012). The time structure of leg movement activity during sleep: The theory behind the practice. *Sleep Medicine*, 13(4), 433–441. <https://doi.org/10.1016/j.sleep.2011.10.027>
- Ferri, R., DelRosso, L. M., Silvani, A., Cosentino, F. I. I., Picchietti, D. L., Mogavero, P., Manconi, M., & Bruni, O. (2020). Peculiar lifespan changes of periodic leg movements during sleep in restless legs syndrome. *Journal of Sleep Research*, 29(3), e12896. <https://doi.org/10.1111/jsr.12896>
- Ferri, R., Fulda, S., Allen, R. P., Zucconi, M., Bruni, O., Chokroverty, S., Ferini-Strambi, L., Frauscher, B., Garcia-Borreguero, D., Hirshkowitz, M., Högl, B., Inoue, Y., Jahangir, A., Manconi, M., Marcus, C. L., Picchietti, D. L., Plazzi, G., Winkelman, J. W., Zak, R. S., & European Restless Legs Syndrome Study, Group. (2016). World Association of Sleep Medicine (WASM) 2016 standards for recording and scoring leg movements in polysomnograms developed by a joint task force from the international and the European restless legs syndrome study groups (IRLSSG and EURLSSG). *Sleep Medicine*, 26, 86–95. <https://doi.org/10.1016/j.sleep.2016.10.010>
- Ferri, R., Manconi, M., Arico, D., Sagrada, C., Zucconi, M., Bruni, O., Oldani, A., & Ferini-Strambi, L. (2010). Acute dopamine-agonist treatment in restless legs syndrome: Effects on sleep architecture and NREM sleep instability. *Sleep*, 33(6), 793–800. <https://doi.org/10.1093/sleep/33.6.793>
- Ferri, R., Mogavero, M. P., Bruni, O., Picchietti, D. L., & DelRosso, L. M. (2023). Periodic leg movements during sleep associated with antidepressants: A meta-analysis. *Neuroscience and Biobehavioral Reviews*, 148, 105126. <https://doi.org/10.1016/j.neubiorev.2023.105126>
- Ferri, R., Mogavero, M. P., Bruni, O., Picchietti, D. L., Kapoor, V., & DelRosso, L. M. (2022). Leg movements during sleep in children treated with serotonergic antidepressants. *Sleep*, 45(3), zsab236. <https://doi.org/10.1093/sleep/zsab236>
- Fulda, S., & Wetter, T. C. (2008). Where dopamine meets opioids: A meta-analysis of the placebo effect in restless legs syndrome treatment studies. *Brain*, 131(Pt 4), 902–917. <https://doi.org/10.1093/brain/awm244>
- Garcia-Borreguero, D., Cano-Pumarega, I., Garcia Malo, C., Cruz Velarde, J. A., Granizo, J. J., & Wanner, V. (2019). Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. *Sleep Medicine*, 55, 74–80. <https://doi.org/10.1016/j.sleep.2018.11.025>
- Garcia-Borreguero, D., Cano-Pumarega, I., & Marulanda, R. (2018). Management of treatment failure in restless legs syndrome (Willis-Ekbom disease). *Sleep Medicine Reviews*, 41, 50–60. <https://doi.org/10.1016/j.smrv.2018.01.001>
- Garcia-Borreguero, D., Larrosa, O., de la Llave, Y., Verger, K., Masramon, X., & Hernandez, G. (2002). Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study. *Neurology*, 59(10), 1573–1579. <https://doi.org/10.1212/wnl.59.10.1573>
- Geng, C., Yang, Z., Zhang, T., Xu, P., & Zhang, H. (2022). Polysomnographic nighttime features of restless legs syndrome: A systematic review and meta-analysis. *Frontiers in Neurology*, 13, 961136. <https://doi.org/10.3389/fneur.2022.961136>
- Inoue, Y., Hirata, K., Kuroda, K., Fujita, M., Shimizu, T., Emura, N., Uchimura, N., Kagimura, T., Sha, K., & Nozawa, T. (2010). Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study. *Sleep Medicine*, 11(1), 11–16. <https://doi.org/10.1016/j.sleep.2009.03.009>
- Kaye, C. M., & Nicholls, B. (2000). Clinical pharmacokinetics of ropinirole. *Clinical Pharmacokinetics*, 39(4), 243–254. <https://doi.org/10.2165/00003088-200039040-00001>
- Kim, J., Kim, J. R., Park, H. R., & Joo, E. Y. (2024). Sex-specific patterns of discomfort in patients with restless legs syndrome. *Journal of Clinical Sleep Medicine*, 20(2), 253–259. <https://doi.org/10.5664/jcsm.10848>
- Kompoliti, K., Adler, C. H., Raman, R., Pincus, J. H., Leibowitz, M. T., Ferry, J. J., Blasucci, L., Caviness, J. N., Leurgans, S., Chase, W. M., Yones, L. C., Tan, E., Carvey, P., & Goetz, C. G. (2002). Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. *Neurology*, 58(9), 1418–1422. <https://doi.org/10.1212/wnl.58.9.1418>
- Kvernmo, T., Houben, J., & Sylte, I. (2008). Receptor-binding and pharmacokinetic properties of dopaminergic agonists. *Current Topics in Medicinal Chemistry*, 8(12), 1049–1067.
- Lanza, G., DelRosso, L. M., & Ferri, R. (2022). Sleep and homeostatic control of plasticity. *Handbook of Clinical Neurology*, 184, 53–72. <https://doi.org/10.1016/B978-0-12-819410-2.00004-7>
- Lanza, G., Fisicaro, F., Cantone, M., Pennisi, M., Cosentino, F. I. I., Lanuzza, B., Tripodi, M., Bella, R., Paulus, W., & Ferri, R. (2023). Repetitive transcranial magnetic stimulation in primary sleep disorders. *Sleep Medicine Reviews*, 67, 101735. <https://doi.org/10.1016/j.smrv.2022.101735>
- Linazasoro, G. (2008). Conversion from dopamine agonists to cabergoline: An open-label trial in 128 patients with advanced Parkinson disease. *Clinical Neuropharmacology*, 31(1), 19–24. (NOT IN FILE).
- Liu, G. J., Wu, L., Wang, S. L., Ding, L., Xu, L. L., Wang, Y. F., & Chang, L. Y. (2016). Incidence of augmentation in primary restless legs syndrome patients may not be that high: Evidence from a systematic review and meta-analysis. *Medicine (Baltimore)*, 95(2), e2504. <https://doi.org/10.1097/MD.0000000000002504>
- Manconi, M., Ferri, R., Zucconi, M., Clemens, S., Rundo, F., Oldani, A., & Ferini-Strambi, L. (2011). Effects of acute dopamine-agonist treatment in restless legs syndrome on heart rate variability during sleep. *Sleep Medicine*, 12(1), 47–55. <https://doi.org/10.1016/j.sleep.2010.03.019>
- Manconi, M., Ferri, R., Zucconi, M., Oldani, A., Fantini, M. L., Castronovo, V., & Ferini-Strambi, L. (2007). First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. *Sleep Medicine*, 8(5), 491–497. <https://doi.org/10.1016/j.sleep.2006.10.008>
- Manconi, M., Ferri, R., Zucconi, M., Oldani, A., Giarolli, L., Bottasini, V., & Ferini-Strambi, L. (2011). Pramipexole versus ropinirole: Polysomnographic acute effects in restless legs syndrome. *Movement Disorders*, 26(5), 892–895. <https://doi.org/10.1002/mds.23543>
- Manconi, M., Garcia-Borreguero, D., Schormair, B., Videnovic, A., Berger, K., Ferri, R., & Dauvilliers, Y. (2021). Restless legs syndrome. *Nature Reviews. Disease Primers*, 7(1), 80. <https://doi.org/10.1038/s41572-021-00311-z>
- Manconi, M., Zavalko, I., Bassetti, C. L., Colamartino, E., Pons, M., & Ferri, R. (2014). Respiratory-related leg movements and their relationship with periodic leg movements during sleep. *Sleep*, 37(3), 497–504. <https://doi.org/10.5665/sleep.3484>
- Medzikovic, L., Azem, T., Sun, W., Rejali, P., Esdin, L., Rahman, S., Dehghanitafati, A., Aryan, L., & Eghbali, M. (2023). Sex differences in therapies against myocardial ischemia-reperfusion injury: From basic science to clinical perspectives. *Cells*, 12(16), 2077. <https://doi.org/10.3390/cells12162077>
- Mehta, J. M., & Manson, J. E. (2024). The menopausal transition period and cardiovascular risk. *Nature Reviews. Cardiology*, 21(3), 203–211. <https://doi.org/10.1038/s41569-023-00926-7>
- Mogavero, M. P., DelRosso, L. M., Lanza, G., Lanuzza, B., Bruni, O., Strambi, L. F., & Ferri, R. (2024). Changes in time structure of periodic leg movements during sleep in restless legs syndrome: Effects of sex and age. *Sleep Medicine*, 115, 137–144. <https://doi.org/10.1016/j.sleep.2024.01.024>

- Mogavero, M. P., Mezzapesa, D. M., Savarese, M., DelRosso, L. M., Lanza, G., & Ferri, R. (2021). Morphological analysis of the brain sub-cortical gray structures in restless legs syndrome. *Sleep Medicine*, 88, 74–80. <https://doi.org/10.1016/j.sleep.2021.10.025>
- Mogavero, M. P., Salemi, M., Lanza, G., Rinaldi, A., Marchese, G., Ravo, M., Salluzzo, M. G., Antoci, A., DelRosso, L. M., Bruni, O., Ferini-Strambi, L., & Ferri, R. (2024). Unveiling the pathophysiology of restless legs syndrome through transcriptome analysis. *iScience*, 27(4), 109568.
- Rocchi, C., Albanese, M., Placidi, F., Romigi, A., Lauretti, B., Marfia, G. A., Liguori, C., Marciari, M. G., Mercuri, N. B., & Izzi, F. (2015). Chronic dopaminergic treatment in restless legs syndrome: Does it affect the autonomic nervous system? *Sleep Medicine*, 16(9), 1071–1076. <https://doi.org/10.1016/j.sleep.2015.04.016>
- Saletu, M., Anderer, P., Saletu-Zyhlarz, G., Hauer, C., & Saletu, B. (2002). Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. *European Archives of Psychiatry and Clinical Neuroscience*, 252(4), 185–194. <https://doi.org/10.1007/s00406-002-0380-7>
- Silber, M. H., Buchfuhrer, M. J., Earley, C. J., Koo, B. B., Manconi, M., Winkelman, J. W., & Scientific and Medical Advisory Board of the Restless Legs Syndrome Foundation. (2021). The Management of Restless Legs Syndrome: An updated algorithm. *Mayo Clinic Proceedings*, 96(7), 1921–1937. <https://doi.org/10.1016/j.mayocp.2020.12.026>
- Sokoloff, P., & Le Foll, B. (2017). The dopamine D3 receptor, a quarter century later. *European Journal of Neuroscience*, 45(1), 2–19.
- Tamargo, J., Caballero, R., & Mosquera, E. D. (2023). Sex and gender differences in the treatment of arterial hypertension. *Expert Review of Clinical Pharmacology*, 16(4), 329–347. <https://doi.org/10.1080/17512433.2023.2189585>
- Walters, A. S., LeBrocq, C., Dhar, A., Hening, W., Rosen, R., Allen, R. P., & Trenkwalder, C. (2003). Validation of the international restless legs syndrome study group rating scale for restless legs syndrome. *Sleep Medicine*, 4(2), 121–132.
- Williams, O. O. F., Coppolino, M., George, S. R., & Perreault, M. L. (2021). Sex differences in dopamine receptors and relevance to neuropsychiatric disorders. *Brain Sciences*, 11(9), 1199.
- Winkelman, J. W., & Jaros, M. J. (2018). Predictors of clinical response in a double-blind placebo controlled crossover trial of gabapentin enacarbil for restless legs syndrome. *Sleep Medicine*, 48, 1–7. <https://doi.org/10.1016/j.sleep.2018.04.001>
- Yost, K. E., Cummings, J. A., & Becker, J. B. (2019). Oestradiol influences on dopamine release from the nucleus accumbens shell: Sex differences and the role of selective oestradiol receptor subtypes. *British Journal of Pharmacology*, 176(21), 4136–4148. <https://doi.org/10.1111/bph.14531>

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Mogavero, M. P., Antelmi, E., Lanza, G., Marelli, S., Castelnuovo, A., Tinazzi, M., DelRosso, L. M., Silvestri, R., Ferri, R., & Ferini Strambi, L. (2024). Sex-based disparities in dopamine agonist response in patients with restless legs syndrome. *Journal of Sleep Research*, e14311. <https://doi.org/10.1111/jsr.14311>